The Next-Gen GLP-1 Pipeline: What's Coming by 2028 and Should You Wait?
⚡ Key Takeaways
- Once-monthly injectables from Pfizer and Amgen are expected around 2028
- Novo Nordisk's CagriSema (semaglutide + amylin) could arrive late 2026
- Researchers propose dropping GLP-1 entirely — GIP/glucagon-only drugs may work as well
- Muscle-sparing drugs (MariTide) could solve the lean mass loss problem
- Don't wait — current prices are at all-time lows and health damage compounds monthly
Table of Contents
The Next Wave of GLP-1 Medications
The current generation of GLP-1s — Wegovy, Zepbound, and their compounded equivalents — are weekly injections or daily pills. The next generation promises once-monthly dosing, greater weight loss, muscle preservation, and entirely new mechanisms. Here's the pipeline that's most likely to reach your pharmacy.
Once-Monthly Injectables (~2028)
| Company | Drug | Mechanism | Est. Launch |
|---|---|---|---|
| Pfizer | Danuglipron (monthly) | GLP-1 agonist | ~2028 |
| Amgen | MariTide | GLP-1/GIP + anti-activin | ~2028 |
| Novo Nordisk | CagriSema (next-gen) | Semaglutide + amylin | Late 2026 |
| Roche | CT-996 | GLP-1 (weekly) | ~2027-2028 |
| Structure Therapeutics | GSBR-1290 | GLP-1 (daily oral) | ~2029 |
Beyond GLP-1: The Provocative New Hypothesis
In April 2026, researchers led by Richard DiMarchi and Matthias Tschöp — whose work led to the development of drugs like Zepbound — published rodent and monkey studies showing that targeting GIP and glucagon receptors without GLP-1 could produce comparable weight loss. If validated in humans, this could mean an entirely new class of obesity drugs that sidesteps GLP-1 resistance entirely.
What this means for patients: The next generation isn't just 'better GLP-1s' — it's fundamentally new approaches to weight loss biology. For the 10% with genetic GLP-1 resistance, non-GLP-1 pathways could be the breakthrough they need.
Muscle-Sparing Drugs: The Holy Grail
Amgen's MariTide is generating particular excitement because it combines GLP-1 activity with anti-activin mechanisms that may preserve lean muscle mass during weight loss. AstraZeneca's acquisition of SixPeaks Bio — a muscle-preservation GLP-1 company — signals that the industry sees muscle sparing as the next major differentiator.
If MariTide delivers on its muscle-preservation promise and offers once-monthly dosing, it could fundamentally change the competitive landscape.
Should You Wait?
No. Here's why:
The nearest next-gen drug (Novo Nordisk's CagriSema) may arrive late 2026, but initial pricing will almost certainly be higher than current options — new drugs always launch premium. Monthly injectables from Pfizer and Amgen are 2+ years away. The GIP/glucagon pathway is preclinical in primates.
Meanwhile, obesity-related health damage compounds every month you wait. The cardiovascular, metabolic, and inflammatory benefits of current GLP-1s are proven now. And current prices are at their all-time lowest.
Start Today at the Lowest Prices in History
| Provider | Starting Price | |
|---|---|---|
| Get Thin MD | $119/mo | Check Price → |
| Yucca Health | $149/mo | Check Price → |
| Care Bare Rx | $169/mo | Check Price → |
| Sesame Care | from $199 | Check Price → |
Paid links · Compounded medications are not FDA-approved. Verify pricing on provider's site.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Prices are estimates based on publicly available information as of April 2026 and may not reflect current costs. Always verify pricing directly with providers. Compounded medications are NOT FDA-approved. Consult a healthcare provider before starting any medication.
Affiliate Disclosure: GLP-1 Pricelist may earn commissions from provider links. This does not influence our price reporting or recommendations. Full disclosure →